The FDA has approved the AstraZeneca drug MOVANTIK™ (naloxegol), a once-daily oral medication for the treatment of opioid induced constipation in adults with chronic noncancer pain.
Opioids bind to mu-receptors in the central nervous system and therefore offer pain relief, but they also bind to mu-receptors in the gastrointestinal tract, which can cause extreme constipation. MOVANTIK (naloxegol) is a peripherally-acting mu-opioid receptor antagonist medication.Although currently a Schedule II (controlled substance) drug, MOVANTIK (naloxegol) may be descheduled by the DEA at the request of AstraZeneca because it “has no risk of abuse or dependency.” MOVANTIK (naloxegol) should be available in 2015.
To read the article, click here.
Posted on September 18, 2014